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1. Introduction 
General anesthetics have been used in clinical practice since the middle of the XIXth century, 
but their molecular mechanisms of action on the nervous system remains poorly 
understood. The main targets of most inhalational anesthetic are pentameric ligand-gated 
ion channels such as inhibitory GABAA (-amino-butyric acid) receptors whose activity is 
potentiated by general anesthetics. However, the main targets of gaseous anesthetics like 
xenon or nitrous oxide are excitatory NMDA (N-methyl-D-aspartate) receptors and nicotinic 
acetylcholine receptors whose activity is inhibited by gaseous anesthetics (Campagna et al., 
2003; Franks, 2008). The use of gaseous anesthetics became widely applicable in the 
nineteen-fifties, nitrous oxide being often administrated in complement of halogenated 
anesthetics. Xenon anesthetic properties have been described by Cullen in 1951 (Cullen et 
al., 1951), and is used in anesthesia since mid-2000 (Sanders et al., 2004; Sanders et al., 2005) 
in spite of its excessive cost,  a major obstacle to its widespread use (Kennedy et al., 1992). 
Anesthesia is a complex process that refers to several physiologically altered functions. 
Early stages of anesthesia such as amnesia and hypnosis required anesthetic concentrations 
lower than those required to produce deep sedation and reduction of motor and automomic 
responses to noxious stimuli (Campagna et al., 2003).  Scales that assess the in-vivo potency 
of inhaled anesthetics in humans are based on the minimum alveolar anesthetic 
concentrations (MAC) that are associated with well-defined behavioural endpoints. 
Following this, MAC-awake defines the MAC that induces the first stages of anesthesia such 
as amnesia and hypnosis, and MAC-immobility defines the MAC that produces deep 
sedation and suppresses movement in response to a noxious stimuli. 
Anesthesia mechanisms were for a long time though to be mediated by non-specific 
membranous perturbation (Trudell, 1977). This membranous theory was based on the 
Meyer-Overton rule that showed an almost perfect relationship between the anesthetic 
property of a chemical compound and its solubility in olive oil or benzene. However, more 
and more exceptions were found to the Meyer-Overton rule such as the non-immobilizers 
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predicted to be potent anesthetics which indeed produced amnesia but not anesthesia or the 
eniantomers which have the same solubility in lipids but different anesthetic potencies 
(Campagna et al., 2003). Since the mid-1980, general anesthetics are though to act by 
disrupting protein functions (Franks et al., 1984; Franks et al., 1994). Chemical compounds 
that cross the blood brain barrier are generally soluble in lipids and could explain the 
Meyer-Overton rule (Franks, 2008). Anesthetics act mainly at ionotropic receptors which 
play a key role in regulation of ions’ concentration on each side on the cytoplasmic 
membrane (Campagna et al., 2003).  For a review of the major targets of general anesthetics 
and their effects, see (Yamakura et al., 2000). 
Xenon and nitrous oxide have been shown in 1998 to be effective inhibitors of the NMDA 
receptor (Franks et al., 1998; Jevtovic-Todorovic et al., 1998) which gave them potentially 
interesting neuroprotective properties for treating major brain insults such as cerebral 
ischemia. Cerebral ischemia is indeed a major health problem, constituting the third cause of 
mortality and the first cause of morbidity in industrialized countries. Cerebral stroke is 
provoked by an acute interruption of the cerebral blood flow, leading to an oxygen and 
glucose deprivation for the brain, inducing dramatic dysfunctions in the excitatory 
glutamatergic neurotransmission. The resulting toxic accumulation of glutamate leads to an 
over-stimulation of glutamatergic receptors like the NMDA receptors, this process is called 
glutamate excitotoxicity (Choi et al., 1988; Dirnagl et al., 1999; Lo et al., 2005). The use of 
NMDA receptor antagonists to block the neurotoxic cascade initiated by the glutamate has 
not yet been proven to be clinically efficient in humans, because of the intrinsic 
neurotoxicity of these chemical compounds (Olney et al., 1991). The only treatment today is 
the use of a thrombolytic agent, the tissue-type plasminogen activator (tPA), which 
degrades the insoluble fibrin clots (NINDS, 1995). However, this treatment is only 
applicable in a few number of cases, due to the  hemorrhagic risk which shorten the 
therapeutic window (Lee et al., 1999; Ahmed et al., 2010). The research of new 
neuroprotective drugs thus constitutes a major therapeutic goal. Inert gases are a new class 
of therapeutic agents which have a remarkably safe clinical profile and readily cross the 
blood brain barrier. Moreover, they have low solubility in blood, which is advantageous in 
terms of rapid inflow and washout. Gases have thus the great advantages to present a 
reducing risk of neurotoxic side effects, compared to chemical neuroprotective drugs, 
especially at the low concentrations used for neuroprotection.  
Nitrous oxide and xenon reduce ischemic neuronal death in an in-vivo model of transient 
cerebral ischemia in rats and decrease the NMDA-induced Ca2+ influx on neuronal cell 
cultures studied by in-vitro calcium video microscopy (David et al., 2003). These two gases 
produce the same effect than memantine, a low-affinity antagonist of NMDA receptor which 
is already used in clinics for neurodegenerative disease treatments (David et al., 2006). 
Investigations in rodents have confirmed that xenon at subanesthetic concentrations of 
about 50 vol% provides maximal neuroprotection, even when given 2 to 4 h after the insult 
onset (Ma et al., 2005; Dingley et al., 2006; David et al., 2008). Nitrous oxide (Haelewyn et al., 
2008) and argon (David et al., submitted) which are less expensive gases than xenon, possess 
mild-to-moderate neuroprotective properties against excitotoxic insults and hypoxic-
ischemic injuries. 
However, xenon and nitrous oxide inhibit tPA-induced thrombolysis, preventing their use 
during the intra-ischemic period. When administrated after the reperfusion, xenon has 
beneficial effect by suppressing ischemic brain damage and tPA-induced brain hemorrhages 
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(David et al., 2010) while nitrous oxide reduces ischemic brain damage but increases tPA-
induced brain hemorrages (Haelewyn et al., 2011). 
Xenon is thus a very promising neuroprotective drug with few or no adverse side effects in 
models of acute ischemic stroke or perinatal hypoxia-ischemia (Homi et al., 2003; Ma et al., 
2003; Abraini et al., 2005; David et al., 2008; Luo et al., 2008). Despite this, the widespread 
clinical use of xenon is limited by its scarceness and excessive cost of production, even if 
close xenon delivery systems are now being developed. 
Using a mixture of xenon and another anesthetic gas like nitrous oxide (Marassio et al., 
2011), argon (David et al., submitted), or helium (David et al., 2009) could combine the 
efficiency of xenon and the low cost and availability of the second gas and is thought to be a 
cost-efficient strategy.  
Argon is an inert gas which is easily available and has no narcotic nor anesthetic action at 
ambient pressure. It presents some mild to moderate neuroprotective properties (David et 
al., submitted). Argon, contrary to xenon and nitrous oxide, may act directly by potentiating 
GABA neurotransmission at the GABAA receptor (Abraini et al., 2003).  
Krypton is significantly less potent as an anesthetic agent than xenon, consistently with the 
Meyer-Overton rule which shows that krypton anesthetic potency is four fold less than 
xenon potency (Cullen et al., 1951; Kennedy et al., 1992). 
Xenon, which has the highest solubility in lipids, also has the highest anesthetic potency 
(i.e. the lowest MAC-immobility) compared to krypton and argon (Table 1). Xenon also 
has the highest polarizability due to its high number of electron, compared to krypton and 
argon, so is predicted to be the gas which interact the most with proteins (Quillin et al., 
2000).   
 
Gas Number 
of 
electrons 
Polarizability 
(Å3) 
van der 
Waals 
radius (Å) 
Solubility 
in lipids 
MAC-
immobility 
(bar) 
Ar 18 1.64 1.91 0.14 27 
Kr 36 2.48 2.03 0.43 7.31 
Xe 54 4.04 2.21 1.17 1.61 
Table 1. Physical and anesthetic properties of argon, krypton and xenon (from (Koblin et al., 
1998; Quillin et al., 2000; Ruzicka et al., 2007)). 
2. Determination of crystallographic structures of proteins under inert gases 
pressure 
To investigate the mechanism of interaction of gases with proteins, a structural approach 
using protein crystallography under gas pressure was developed. Xenon binds reversibly to 
proteins through non-covalent, weak energy van der Waals forces (Ewing et al., 1970). The 
first structures of protein – xenon complexes were solved in 1965 with myoglobin and 
haemoglobin under a xenon pressure of 2.5 bar, evidencing a xenon binding site in these 
two globins (Schoenborn, 1965; Schoenborn et al., 1965). At a pressure of 7 bar, four xenon 
binding sites were found in myoglobin indicating that the number of xenon binding sites 
rises with pressure (Tilton et al., 1984).  
Since then, many structures of protein-xenon complexes were solved, with xenon used as a 
heavy atom in isomorphous replacement phasing method (MIR), because xenon has a high 
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number of electrons (54 e-) and binds with very little perturbation of the protein structure 
(Vitali et al., 1991; Schiltz et al., 1994; Bourguet et al., 1995; Colloc'h et al., 1997). On the other 
hand, krypton, though lighter than xenon, was popularized as an internal reference in 
anomalous phasing techniques MAD or SAD (Schiltz et al., 1997; Cohen et al., 2001) thanks 
to its absoption K edge at a convenient and useful wavelength easy to tune at all 
synchrotron places; for a review, see (Schiltz et al., 2003).  
Xenon and other noble gas binds primarily in pre-existing hydrophobic cavities or pockets, 
very often empty in the native gas-less structures (Prangé et al., 1998). Xenon diffusing 
through protein atoms reaches easily its completely buried binding sites. Xenon was also 
used as an oxygen probe, based on the hypothesis that xenon and dioxygen would have 
equivalent binding sites (Duff et al., 2004). The comparison of the binding mode of xenon, 
krypton and argon was done on the phage T4 lysozyme, showing that gas occupancy rises 
with gas size and polarizability (Xe > Kr > Ar) (Quillin et al., 2000). 
X-ray diffraction data of a protein under xenon pressure are collected either at liquid 
nitrogen temperature (100 K) or at room temperature. In the first case, the crystal inserted in 
a cryo-loop is placed in a xenon pressure chamber for a given time, then immediately after 
frozen in liquid nitrogen, to minimize the amount of xenon which could escape the protein 
crystal. The determination of the gas pressure within the crystal is thus quite imprecise. For 
the present study which needs the determination of protein structures under a large range 
of gas pressures, we have used a pressurisation cell in capillary, designed and developed for 
the preparation of isomorphous xenon derivatives (Schiltz et al., 1994; Schiltz et al., 2003). 
 
 
Fig. 1. The pressurisation cell setting. A. Connection between the five elements shown in B. 
1- Xenon bottle, 2- Gas regulator, 3- High precision gauge, 4- Bleeding valve, 5- 
Pressurisation cell. 
Typically, a crystal of protein is placed inside a quartz capillary mounted on the 
pressurisation cell. The pressurisation cell is fixed on a standard goniometer head, and 
connected to a gas bottle. The pressure within the cell is determined precisely with a 
calibrated Ashcroft precision gauge (Figure 1). The pressure is maintained constant during 
all the data collection. 
For the present study, we have investigated three different enzymes, urate oxidase, elastase 
and lysozyme in complex with three gases, xenon, krypton and argon. In urate oxidase, 
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xenon binds primarily in a large buried hydrophobic cavity close to the active site (Colloc'h 
et al., 2007; Marassio et al., 2011). Xenon was used as an isomorphous derivative during the 
determination of urate oxidase structure (Colloc'h et al., 1997). In elastase, like in most of the 
serine proteases, xenon binds within the specificity pocket S1 of the active site (Schiltz et al., 
1995). In lysozyme, xenon binds weakly in an internal cavity and mainly in a pocket located 
at a crystallographic interface (Schiltz et al., 1997; Prangé et al., 1998). 
One of the drawbacks of using X-ray crystallography is the requirement to have a high gas 
pressure to be able to observe it in the electron density map. A gas pressure about 5 to 10 
fold the physiological concentration is estimated to correspond to physiological conditions 
(Miller, 2002). In the present study, gas pressure ranges from 1 to 40 bar in order to reach a 
maximum occupancy at saturation, however, only the data between 5 and 10 bar can be 
compared to physiological conditions. 
In the present study, diffraction data were collected at room temperature at the BM14, BM16 
and BM30A beamlines at the European Synchrotron Radiation Facility (Grenoble, France). 
Detectors used were a MAR CCD detector for BM14, an ADSC Q210r CCD detector for 
BM16 and an ADSC Q315r CCD detector for BM30A. Data were indexed and integrated by 
DENZO and scaled independently and reduced using SCALEPACK, both programs from the 
HKL package (Otwinowski et al., 1997) or indexed and integrated by MOSFLM (Leslie, 2006) 
or XDS (Kabsch, 2010) and scaled by SCALA; intensities were converted in structure factor 
amplitudes and put on absolute scale using TRUNCATE and structure refinements were 
carried out by REFMAC (Murshudov et al., 1997), all programs from the CCP4 package 
(Collaborative Computational Project, 1994). The graphics program COOT (Emsley et al., 
2004) was used to visualize |2Fobs – Fcalc| and |Fobs – Fcalc| electron density maps and for 
manual rebuilding. Cavity volume were calculated with the program CastP (Dundas et al., 
2006) with a probe radius of 1.3 Å. Structural figures were prepared using PyMol (deLano 
W.L., DeLano Scientific, Palo Alto, CA, USA). 
3. Structure of urate oxidase under inert gas pressure 
3.1 Structure of urate oxidase under pressure of xenon and nitrous oxide and 
comparison with in-vivo pharmacology effects 
Aspergillus flavus urate oxidase (EC 1.7.3.3) is a homotetrameric enzyme of 301 residues 
per subunit which is involved in the oxidation of uric acid in presence of molecular 
oxygen.  It crystallizes in the orthorhombic space group I222 with one monomer per 
asymmetric unit (cell: a = 79.8 Å, b = 96.2 Å, c = 105.4 Å,  =  =  = 90°). X-ray structures 
of urate oxidase under various pressures of xenon and nitrous oxide have been 
determined. Both gases were bound mainly in an internal cavity close to the active site of 
the enzyme, this cavity being empty in the native gas-less structure (Figure 2). This cavity, 
completely buried within the monomer, is highly hydrophobic, with 86 % of the atoms 
lining the cavity being carbons. Both gases were bound also very weakly to a second 
location, a small extension of a solvent-accessible pocket quite hydrophobic (lined by 75 % 
carbons). The gas occupancy in this second binding site remained very low (less than 30 % 
at 30 bar of pressure). Gas occupancies in the main binding site were high, reaching 
saturation at 100 % for xenon and 60 % for nitrous oxide (Table 2). The main effect of the 
gas was to expand the volume of the cavity where it binds. This expansion increased with 
gas occupancy and hence with gas pressure. 
www.intechopen.com
 
Current Trends in X-Ray Crystallography 
 
290 
 
Fig. 2. Hydrophobic cavity in urate oxidase where xenon is bound (shown as an orange 
sphere). This cavity is close to the active site, where the competitive inhibitor 8-azaxanthine 
is located (colored in stick by atomic type). The solvent-accessible surface is shown in mesh 
representation colored by atomic type. 
The ratio of gas-induced expansion of the hydrophobic cavity volume for xenon and nitrous 
oxide in urate oxidase, which could be considered as a model of globular proteins where 
inert gases bind and whose activity is disrupted by their presence, ranged between 1.1 and 
1.5, depending on the applied pressure (Table 2). For the pressures estimated to correspond 
to physiological conditions (i.e. 5-10 bar), this ratio ranged between 1.3 and 1.5. 
 
Xenon 
pressure 
(bar) 
Xe 
occ. 
(%) 
Main 
Xe-
induced 
expansion 
N2O 
occ. 
(%) 
main 
N2O-
induced 
expansion 
(%) 
Ratio 
Xe/N2O- 
induced 
expansion 
Xe 
occ. 
(%) 
2nd 
N2O 
occ. 
(%) 
2nd 
5 18 10.8 0 8.5 1.3 0 0 
10 60 18.8 40 12.4 1.5 10 0 
15 100 19.5 50 17.8 1.1 20 0 
20 100 23.1 60 18.4 1.3 22 0 
30 100 23.2 60 20.1 1.2 27 25 
Table 2. Gas pressure, xenon and nitrous oxide occupancies in the main binding site, gas-
induced expansion of the main gas binding site, ratio of expansion, and xenon and nitrous 
oxide occupancies in the secondary binding site. 
If we compared these data with in-vivo pharmacology studies, we noticed that this ratio 
corresponded to the ratio of the narcotic potency of xenon compared to nitrous oxide (about 
1.38) as estimated by the concentration of gas necessary to induce loss of righting reflex in 
rodents (Koblin et al., 1998; David et al., 2003), considered to be a behavioural endpoint 
closely related to MAC-awake (Campagna et al., 2003).  
In comparison, the ratio of gas-induced volume expansion for xenon and nitrous oxide in 
annexin V, a protein which could be considered as a prototype of NMDA receptor for its 
properties of ion selectivity and voltage gating (Demange et al., 1994), did not correspond to 
the ratio of anesthetic potency of xenon and nitrous oxide. However, when considering 
urate oxidase and annexin V together as a model of simultaneous occupancy of globular 
proteins and ion-channel receptors, the ratio of gas-induced expansion for xenon and 
Xenon
8-azaxanthine 
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nitrous oxide was close to 1, a value that corresponded to the ratio of anesthetic potency of 
xenon compared to nitrous oxide, as assessed by their MAC-immobility (Russell et al., 1992; 
Koblin et al., 1998).  
These relationships between gas-induced structural effect and gas-induced narcotic effect 
allowed proposing a step-by-step mechanism of anesthesia. Gas would first bind to globular 
cytosolic or extracellular proteins which possess suitable gas binding site easily accessible. 
Gas-induced disruption of their function would lead to the early stages of anesthesia, i.e. 
amnesia and hypnosis. When all easily accessible gas binding sites are occupied, gas would 
then bind to neuronal channel which possess smaller gas binding sites, the disruption of 
their function would lead to surgical anesthesia, i.e. deep sedation and lack of responses to 
noxious stimuli (Colloc'h et al., 2007). 
3.2 Structure of urate oxidase under pressure of xenon and nitrous oxide and 
comparison with in-vitro activity assays 
As mentioned above, the main gas binding site in urate oxidase is very close to the active 
site (Figure 2). To investigate if gas occupancy and gas-induced volume expansion may have 
some functional relevance, we performed activity assays on urate oxidase in presence either 
of air, and either of a mixture of 75 vol % xenon or nitrous oxide and 25 vol % oxygen. To 
evaluate the alternative therapeutic strategy of using a mixture of xenon and nitrous oxide 
to combine the efficiency of xenon and the low cost and availability of nitrous oxide, we 
have also determined the structure of urate oxidase with various pressure of an equimolar 
mixture of xenon and nitrous oxide, and we have performed an activity assay in presence of 
a mixture of 37.5 vol% xenon, 37.5 vol% N2O and 25 vol% oxygen. We found that Xe:N2O 
induced a higher expansion of the cavity volume than pure xenon, which in turn induced a 
higher expansion than N2O as seen above. In-vitro activity assays revealed that Xe:N2O-
induced inhibition was higher than Xe-induced inhibition, itself higher than N2O-induced 
inhibition. The relationship between structural effect of the gas, i.e. gas-induced volume 
expansion, and the functional effect of the gas, i.e. gas-induced inhibition of the enzymatic 
reaction, highlighted the way by which gases might disrupt protein function through an 
indirect mechanism (Marassio et al., 2011). 
The role of the void hydrophobic cavity in the catalytic mechanism was thus demonstrated 
by the activity assays in presence of gas. This functional role was also suggested by the high-
pressure structural and functional study of urate oxidase. Under high hydrostatic pressure 
(150 Ma; 1500 bar) the volume of the cavity was reduced as expected, while the volume of 
the active site was expanded. High pressure also inhibited the catalytic mechanism of urate 
oxidase, this loss of activity being a loss of substrate affinity (Girard et al., 2010).  
In both cases (gas or pressure), there was a loss of flexibility of the cavity, either by the gas 
presence which induced an expansion and inhibited its contraction, either by high pressure 
which induced a cavity contraction but inhibited its expansion. The role of the cavity in the 
functional mechanism of urate oxidase seems then to give some flexibility to the active site 
to allow a structural fit for the ligand in the active site. 
3.3 Structure of urate oxidase under pressure of krypton and comparison with gas 
solubility in lipids 
Structures of urate oxidase under krypton pressure of 2 to 30 bar were determined in the 
present study. Krypton was bound to the exact same location than xenon, in the 
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hydrophobic cavity close to the active site. Krypton occupancy increased with the applied 
pressure up to 45 % at 30 bar (Table 3). Like xenon, krypton was also weakly bound to a 
secondary binding site at the bottom of a solvent-accessible pocket, but only at pressure 
above 20 bar. 
For an identical pressure, krypton occupancy was always lower than xenon occupancy 
(Figure 3A). Xenon which has a higher number of electrons than krypton has a higher 
polarizability (Table 1) and binds thus with a higher occupancy, as already observed in the 
case of phage T4 lysozyme (Quillin et al., 2000). 
 
Krypton 
pressure 
(bar) 
Resolution 
(Å) 
Occ. in 
main 
binding 
site (%) 
Kr-
induced 
expansion 
(%) 
Xe-
induced 
expansion 
(%) 
Ratio 
Xe / Kr 
induced 
expansion 
Occ. in 
2nd 
binding 
site (%) 
2 1.60 10 3.2 3.3 1.0 0 
5 1.60 15 4.1 10.8 2.6 0 
10 1.55 20 11.4 18.8 1.6 0 
20 1.65 40 12.8 23.1 1.8 10 
30 1.65 45 15.2 23.2 1.5 15 
Table 3. Krypton pressure, resolution of the crystallographic structure, krypton occupancy 
in the main binding site, krypton-induced and xenon-induced volume expansion of the 
main binding site, ratio of the Xe and Kr-induced volume expansion and krypton occupancy 
in the secondary binding site. 
If one refers to the Meyer-Overton rule, the narcotic potency of a gas would be related to its 
solubility in lipids. The ratio of solubility in lipids of xenon compared to krypton is 1.17 / 
0.14 = 2.7 (Table 1), a value which correspond to the ratio of Xe and Kr-induced volume 
expansion at the pressure of 5 bar, well within the range of pressure estimated to 
correspond to physiological condition. This result confirmed what was shown previously 
when comparing the structural-induced effect of xenon and nitrous oxide on urate oxidase 
to their in-vivo effect as evaluated by their MAC-awake (Colloc'h et al., 2007). However, the 
MAC-immobility which prevents response to noxious stimuli for xenon in man is about 4.5 
higher than the MAC-immobility of krypton (Table 1), which does not correspond to the 
structural Xe- and Kr-induced structural effect in urate oxidase, considered as a model for 
globular protein whose function is disrupted by the presence of gas. 
3.4 Structure of urate oxidase under pressure of argon and comparison with in-vivo 
pharmacology study 
Structures of urate oxidase under argon pressure of 10 to 65 bar were determined in the 
present study. Argon was bound to the exact same location than xenon and krypton, in the 
large hydrophobic cavity close to the active site. Argon became visible in the electron 
density map at a pressure of 30 bar and above, with an occupancy factor of 40 % at a 
pressure of 65 bar (Table 4). 65 bar is the maximum pressure which could be reach in the 
quartz capillary; above that pressure, the risk of breakage of the capillary became very high. 
At the same pressure, argon occupancy was always lower than krypton and xenon 
occupancies (Figure 3A). In the secondary binding site where xenon and krypton bind very 
weakly, no argon is detectable in the electron density map, even at a pressure of 65 bar.  
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Argon 
pressure 
(bar) 
Resolution 
(Å) 
Occ. in main 
binding site 
(%) 
Ar-induced 
expansion 
(%) 
Xe- 
induced 
expansion 
(%) 
Ratio 
Xe / Ar 
Indiced 
expansion 
10 1.65 0 7.1 20.7 2.9 
20 1.90 0 11.0 24.6 2.2 
25 1.60 20 13.4   
30 1.60 20 12.3 24.6 2 
35 1.60 20 14.1   
40 1.75 20 10.3   
45 1.60 25 11.1   
55 1.60 30 10.7   
65 1.60 40 16.4   
Table 4. Argon pressure, resolution of the crystallographic structure, argon occupancy, 
argon-induced and xenon-induced cavity volume expansion, and ratio of the Xe and Ar-
induced volume expansion. 
 
 
Fig. 3. A. Gas occupancy as a function of pressure. B. Gas-induced expansion of the main 
binding site as a function of pressure. 
As for the two other nobles gas, the main effect of argon was to expand the volume of the 
cavity where it was bound. However, due to its quite low occupancy factor and its small 
size, the argon-induced expansion remained low, around 10 % of expansion except for the 
pressure of 65 bar where expansion reached 16 % (Table 4). For pressure of 10 and 20 bar 
where argon was not detectable in the electron density map, there was already a volume 
expansion indicating with little doubt the presence of argon within the cavity (Table 4, 
Figure 3B). 
The ratio of Xe- and Ar-induced expansions of the cavity volume was 2.9 for a pressure of 10 
bar, which did not correspond to their inverse ratio of MAC-immobility (27/1.61 = 16.8) nor 
their ratio of solubility in lipids (1.17 / 0.14 = 8.4) (Table 1). However, argon is not narcotic 
at ambient pressure and needs to be pressurised to have some narcotic action. 
In order to allow comparison of the effects of argon and xenon in urate oxidase, we further 
calculated the theoretical expansion of the gas binding cavity produced by argon at 100 % 
occupancy according to a linear regression model. For occupancy of 100% of argon, the 
corresponding volume expansion would be of 23.3 % (Figure 4A). According to a linear 
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regression model, this expansion would be reach for a pressure of 164 bar (Figure 4B). This 
pressure corresponds to about ten fold the pressure of 14 to 17 bar at which argon is known 
to produces narcosis in rodents (Abraini et al., 1998; Koblin et al., 1998). 
 
 
Fig. 4. Linear regression model for cavity volume expansion as a function of occupancy (A) 
and as a function of pressure (B). 
In addition, it should be mentioned that these estimated values for argon were also 
consistent with crystallographic data that have demonstrated that xenon at full occupancy 
(pressure of about 20 bar) produces a similar maximal expansion around 23-25 % of the gas 
binding site (Table 2). This is consistent with the fact that the ratio between the efficient 
estimated pressure of argon and the efficient experimental pressure of xenon at producing 
full occupancy and maximal expansion of the gas binding site (164 / 20 = 8.2) is similar to 
the ratio of their solubility in lipids (1.17 / 0.14 = 8.4) as predicted by the Meyer-Overton 
rule (Abraini et al., 2003; Campagna et al., 2003). 
Argon is narcotic only in hyperbaric condition. At ambient pressure, argon may thus have a 
very limited influence on its target function. Since one of the major effect of hydrostatic 
pressure is to contract the volume of internal cavities (Girard et al., 2010), it may explain 
why argon needs hyperbaric condition to exert its influence. 
3.5 Conclusion on urate oxidase structures under inert gas pressure 
The three noble gases were bound to an identical location in urate oxidase, within an 
internal hydrophobic cavity. The gas occupancies increased in the sequence argon < krypton 
< xenon, as it was the case for T4 lysozyme (Quillin et al., 2000), who noticed that smaller 
gases do not bind as well as larger ones as a result of their attenuated polarizability. Xenon 
and krypton were bound also weakly in a secondary binding site, while argon was not 
observed even at high pressure. 
The main effect of the gas was to expand the cavity volume where it binds. The ratio of 
expansion was related to the narcotic potency of the gas, as evaluated by their MAC-awake 
or their solubility in lipids. The presence of xenon within the cavity induced an inhibition of 
the catalytic mechanism, with a relationship between gas-induced expansion and gas-
induced inhibition, as shown by the comparison between xenon and nitrous oxide structural 
and functional effects. No activity assays were performed in presence of krypton or argon, 
but we can predict, based on the present structural results, that krypton should induce an 
inhibition of the catalytic mechanism of urate oxidase. However, krypton-induced inhibition 
should be lower than xenon-induced inhibition, according to their relative induced 
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expansion in the range 5-10 bar (Table 3). Argon-induced inhibition should be very low or 
inexistent, according to the very low gas occupancy and argon-induced expansion at a 
pressure of 10 bar (Table 4). 
4. Structure of elastase under inert gas pressure 
4.1 Introduction on elastase structures under inert gas pressure 
Pancreatic porcine elastase (EC 3.4.21.36) is a serine protease of 266 residues which hydrolyzes 
peptide bonds in proteins, its main substrate being elastine. The catalytic triad of elastase is 
composed, as for all serine proteases, of an activated serine (Ser 195) assisted by a proton relay 
(His 57), which acts as a general base, and stabilized through an hydrogen bond by an aspartic 
acid (Asp 102). Pancreatic porcine elastase crystallizes in the orthorhombic space group P212121 
with one monomeric enzyme per asymmetric unit (cell : a = 51.4 Å, b = 58.0 Å, c = 75.3 Å,  =  
=  = 90°). In the crystallographic structure, a sulphate or an acetate ion is bound in the 
oxyanion hole, depending on the concentration of the precipitating agents. The primary 
specificity pocket S1 is a hydrophobic pocket located below the oxyanion hole and the Ser 195 
which is specific for recognition of the peptidic substrate. 
In the crystallographic structures of apo elastase, the S1 pocket was either empty, either 
filled by a water molecule hydrogen-bonded to a water molecule outside of the S1 pocket 
and to an oxygen atom of the sulphate ion (Figure 5A). When this water molecule (termed 
W-S1) was present, its B-factor was quite elevated. In the different crystallographic 
structures of elestase in complex with xenon deposited in the Protein Data Bank, 1C1M 
(Schiltz et al., 1995), 1L1G and 1L0Z (Panjikar et al., 2002), 1UO6 and 2A7C (Mueller-
Dieckmann et al., 2004) and 2OQU (Kim et al., 2007), xenon was bound within the specificity 
pocket S1 in the active site of elastase (Figure 5B). This xenon binding site is moderately 
hydrophobic, lined with 60% carbons. 
 
 
Fig. 5. Elastase shown with its solvent-accessible surface colored by atomic type. A. Native 
gas-less elastase with the water molecule W-S1 in the S1 pocket. B. Elastase in complex with 
xenon (shown as an orange sphere) or in complex with a peptidic inhibitor TFLA (shown in 
cyan in stick representation). 
In the present study, structures of native elastase (gas-less) were determined in the same 
conditions than structures under inert gas pressure, i.e. at room temperature in a quartz 
A B
W-S1 Xe
TFLA
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capillary. Three structures have been solved, at 1.38 Å, 1.7 Å and 1.45 Å resolution. In two 
native structures, the S1 pocket was empty while in one of them, there was the water 
molecule W-S1 with a B-factor of 36.3 Å2. 
4.2 Structure of elastase under pressure of xenon and comparison with in-vitro 
activity assays 
Structures of elastase under xenon pressure from 1 bar to 30 bar were determined in the 
present study. Whatever the applied pressure, xenon was bound to a unique site, within the 
specificity pocket S1, with an occupancy which increased with the applied pressure. 
Occupancy reached 100 % for a pressure of 30 bar (Table 5). The S1 pocket where xenon 
binds is moderately hydrophobic, with 60 % of atoms lining it being carbons. This gas 
binding site is less hydrophobic than the main gas binding site in urate oxidase, which was 
lined by 86 % carbons. The atom the closest to xenon is the side chain atom O of the 
catalytic Ser 195. 
 
Xenon 
pressure 
(bar) 
Resolution 
(Å) 
Occ. (%) Xe-induced 
expansion 
(%) 
1 1.40 15 3.0 
2 1.45 25 3.3 
5 1.50 30 7.8 
10 1.50 70 9.4 
20 1.60 90 12.7 
30 1.65 100 13.6 
Table 5. Xenon pressure, resolution of the crystallographic structure, occupancy and xenon-
induced expansion of the S1 pocket in elastase. 
Whatever the pressure, there was no water molecules in the S1 pocket, so if the water 
molecule W-S1 was present in the native gas-less structure, it was not displaced but 
replaced by xenon. However, xenon did not take the exact location of the W-S1 and was 
closer to the O of the catalytic Ser 195 (3.4 Å instead of 3.8 Å).  
The presence of xenon within the S1 pocket expanded its volume, its expansion rising with 
the applied pressure. However, since the gas was bound directly within the active site, the 
gas-induced inhibition is likely to be a direct inhibition and the expansion by itself has 
probably no functional relevance. Xenon took indeed the place of peptidic inhibitors, like 
the trifluroacetyl-leu-ala (TFLA) known to be an excellent inhibitor of elastase (Li de la 
Sierra et al., 1990) (Figure 5B). 
To investigate the direct inhibition by xenon, we performed activity assays on elastase in 
presence either of air, either of 100 vol % xenon. Initial velocity in presence of xenon when 
compared to air (taken as 100 %) was 81.5 + 2.1 % revealing an inhibition of the catalytic 
activity of elastase of around 20 % by xenon. However, this inhibition was lower than xenon 
occupation in the range 5-10 bar (30 – 70 % occupation). 
Tissue-type plasminogen activator (tPA), the only approved treatment for thrombolysis 
after an ischemic stroke, is also a serine protease. As in the case of elastase, xenon inhibited 
tPA enzymatic activity (David et al., 2010). This inhibition is likely to be a direct inhibition 
with xenon binding directly in the S1 pocket in the active site of tPA. Serine proteases have 
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indeed structurally similar active site with the same catalytic triad which can be easily 
superimposed (Schiltz et al., 1995). The superimposition of the catalytic triad of elastase and 
of tPA suggested that xenon fitted perfectly in the S1 pocket of tPA, thus inhibiting tPA 
enzymatic activity. 
4.3 Structure of elastase under pressure of krypton 
Structures of elastase under pressure of krypton from 2 to 30 bar were determined in the 
present study. Krypton was bound within the S1 pocket, at the exact same location than 
xenon. The water molecule W-S1 if it was present was replaced by the krypton atom. 
Occupancy of krypton reached 70 % at the pressure of 30 bar (Table 6). 
 
Krypton 
pressure 
(bar) 
Resolution 
(Å) 
Occ. (%) Kr-induced 
expansion 
(%) 
2 1.35 20 4.9 
5 1.45 25 4.9 
10 1.50 35 5.8 
20 1.75 50 7.9 
30 1.45 70 8.5 
Table 6. Krypton pressure, resolution of the crystallographic structure, occupancy and 
krypton-induced expansion of the S1 pocket in elastase. 
Krypton occupancy was always lower than xenon occupancy for a same pressure (Figure 6). 
Xenon which is more polarizable was bound with a higher occupancy than krypton. Since 
the gas binding site is only moderately hydrophobic, with a lot of polar atoms lining the gas, 
it is likely that dipole-induced interactions play an important role in gas binding. Like 
xenon, krypton induced an expansion of the S1 pocket where it binds. However, this 
expansion remained quite low, less than 10 %.  
4.4 Structure of elastase under pressure of argon 
Structures of elastase under pressure of argon of 10 to 60 bar were determined in the present 
study. Argon was bound within the S1 pocket, at the exact same location than xenon and 
krypton. Argon occupancy reached 50 % for a pressure of 60 bar (Table 7). For technical 
conditions, it was not possible to reach higher pressure due to the risk of failure of the 
quartz capillary. Argon occupancy was always lower than krypton and xenon occupancy for 
a same pressure, according to a lower polarizablity (Figure 6). 
 
Argon 
pressure 
(bar) 
Resolution 
(Å) 
Occ. (%) B factor 
W-S1 
10 1.35 35 42.5 
20 1.45 35 missing 
30 1.50 40 40.1 
40 1.35 40 missing 
60 1.50 50 missing 
Table 7. Argon pressure, resolution of the crystallographic structure, occupancy and B-factor 
of the water molecule W-S1 if it is present. 
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Fig. 6. Xenon, krypton and argon occupancies as a function of pressure. 
Argon occupancy was higher in elastase than in urate oxidase (Table 4), probably because of 
the smaller size of the gas binding site in elastase which would allow a better binding of 
argon.  
Argon-induced expansion of the S1 pocket was very low and not very significant (less than 
5 %), probably due to the small size of the argon atom.  
Contrary to xenon and krypton cases, when the water molecule W-S1 was present in the 
native gas-less structure, this water molecule remained visible close to the argon electronic 
density (Figure 7), with a lower occupation factor. The distance between the argon atom and 
the W-S1 molecule was about 2.8 Å.  
 
 
Fig. 7. 2Fo-Fc electron density map of elastase under an argon pressure of 10 bar, contoured 
at 1 .  
4.5 Conclusion on elastase structures under inert gas pressure 
In elastase, there is one unique gas binding site, located within the S1 pocket in the active 
site. Contrary to urate oxidase where the gas binding site was an empty cavity, there might 
be a water molecule in the moderately hydrophobic S1 pocket. When present, this water 
molecule was replaced by xenon and krypton, but remained visible close to argon. 
Xenon inhibited directly elastase catalytic activity by taking the place of the substrate, even 
if its inhibition stayed lower than its occupancy. It is also likely that krypton inhibited 
elastase catalytic activity. Since krypton occupancy was lower than xenon occupancy, 
krypton-induced inhibition is expected to be lower than xenon-induced inhibition. In the 
range 5-10 bar, krypton occupancy ranged between 25 and 35%, inducing probably a rather 
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small inhibition of the enzymatic reaction. Argon-induced inhibition of the catalytic reaction 
is likely to be quite low and similar to krypton-induced inhibition, with an occupation of 
argon of 35 % at 10 bar. 
5. Structure of lysozyme under inert gas pressure 
5.1 Introduction on lysozyme structures under inert gas pressure 
Egg white lysozyme C (EC 3.2.1.17) is an enzyme of 129 residues which hydrolyse 
peptidoglycans. It crystallizes in tetragonal space group P43212 with one monomeric enzyme 
per asymmetric unit (cell: a = 79.2 Å, b = 79.2 Å, c = 37.9 Å,  =  =  = 90°). In the different 
crystallographic structures of lysozyme in presence of xenon deposited in the Protein Data 
Bank : 1C10 (Prangé et al., 1998), 2A7D (Mueller-Dieckmann et al., 2004) and 1VAU (Takeda 
et al., 2004), xenon was bound mainly in a pocket at a crystallographic interface (gas binding 
site I or GBS I in Figure 8) and weakly in a small internal cavity (GBS II in Figure 8). In the 
native gas-less structure, a water molecule was present in GBS I, and GBS II was empty. GBS 
I is moderately hydrophobic, lined with 55 % carbons, and GBS II is very hydrophobic, lined 
with 83 % carbons. The occupancy of xenon ranged between 30 and 60% in GBS I and stayed 
beyond 25 % in GBS II. 
 
 
Fig. 8. Xenon binding sites in lysozyme, shown with two symmetrical subunits. A. Xenon 
was bound at the crystallographic interface between two symmetrical monomers (GBS I) 
and a second xenon was bound within a small internal cavity buried within each monomer 
(GBS II) (xenon shown as orange spheres, and lysozyme with its C chain as ribbon, one 
symmetric is colored in green, the second in blue). B. Solvent-accessible surface of two 
symmetrical lysozymes. 
In the structure 1C10, a third xenon was located in the active site, where either two water 
molecules or one water molecule and one chloride ion were found in the other deposited 
structures. In the structure 1VAU, a third xenon was located in another crystallographic 
pocket at the interface between two monomers, where a water molecule was found in the 
other deposited structures. 
In the crystallographic structure of lysozyme under a 55 bar pressure of krypton 1QTK, 
(Schiltz et al., 1997; Prangé et al., 1998),  krypton was bound in the internal cavity (GBS II) 
but not in the crystallographic pocket (GBS I). 
In the present study, the structure of a native gas-less lysozyme was determined in the same 
condition than structures under inert gas pressure, i.e. at room temperature in quartz capillary. 
Two native structures have been solved, at 1.6 Å and 1.55 Å resolution. In both structures, the 
internal cavity GBS II was empty and there was a water molecule in GBS I which had a B-
GBS II GBS II 
GBS  I 
GBS II GBS II 
GBS I 
A B
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factor between 25 and 29 Å2. The volume of the internal cavity GBS II is very small, about 40 
Å3 while the volume of GBS I at a crystallographic interface is larger, around 100 Å3. 
5.2 Structure of lysozyme under pressure of xenon 
The structures of lysozyme under xenon pressure of 10 to 30 bar were determined in the 
present study. Xenon was bound in GBS I with an occupancy which did not increase with 
pressure and remained around 20 and 30 % (which is the double of the occupancy for the 
monomer since the xenon is located at a crystallographic interface). Xenon was also bound 
in GBS II with an occupancy which increased with the applied pressure but which remained 
quite low (20 % occupancy at 30 bar). 
Xenon occupancy in GBS I remained stable whatever the applied pressure and induced 
almost no expansion of its volume (less than 10 %). Xenon location was not exactly 
superposed to the water molecule location present in the native gas-less structure, with a 
distance of 0.6 to 0.7 Å between them. This gas binding site being located at a 
crystallographic interface is likely to be not physiological. 
 
Xenon pressure 
(bar) 
Resolution (Å) Xe occ. in 
GBS I (%) 
Xe occ. in 
GBS II  (%) 
Xe-induced 
expansion of GBS 
II (%) 
10 1.55 30 10 9.1 
15 1.60 20 10 4.6 
20 1.55 30 12 6.9 
25 1.90 24 15 13.6 
30 1.65 30 20 23.4 
Table 8. Xenon pressure, resolution of the crystallographic structures, xenon occupancy in 
GBS I , xenon occupancy in GBS II and xenon-induced expansion of GBS II. 
Xenon occupancy in GBS II remained very low, due to the small size of the cavity (volume 
around 40 Å3). Xenon van der Waals radius is of 2.21 Å, its theoretical volume is thus of 45 
Å3, close to the volume of GBS II. Xenon induced an expansion of the volume of this small 
internal cavity which reached a volume around 50 Å3 for xenon occupancy of 20 %. In the 
range of pressure corresponding to physiological conditions (5 – 10 bar), the occupation of 
xenon in GBS II is likely to be very small (less than 10 %). 
5.3 Structure of lysozyme under pressure of krypton 
The structures of lysozyme under krypton pressure of 5 to 20 bar were determined in the 
present study. No krypton was visible in GBS I whatever the applied pressure, as it was the 
case in the structure determined under a krypton pressure of 55 bar. In all cases, there was a 
water molecule at the exact same location than in the native gas-less structure. Krypton was 
bound weakly in GBS-II and became visible in the electron density map at a pressure of 20 bar. 
Krypton induced an expansion of the volume of GBS II which seemed not related to krypton 
occupancy. However, this krypton-induced expansion of GBS II indicated that krypton was 
present event when it was not visible in the electron density map (Table 9). 
Krypton is smaller than xenon (van der Waals radius of 2.03 Å instead of 2.21 Å, and 
volume of 35 Å3 instead of 45 Å3), it is thus likely than krypton occupancy can reach higher 
value than xenon occupancy in GBS II (Figure 9).  
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Krypton 
pressure (bar) 
Resolution (Å) Kr occ. in 
GBS I (%) 
Kr occ. in 
GBS II  (%) 
Kr-induced 
expansion of 
GBS II (%) 
5 1.55 0 0 12.1 
10 1.60 0 0 4.6 
20 1.55 0 10 14.9 
55 (1QTK) 2.03 0 49 7.1 
Table 9. Krypton pressure, resolution of the crystallographic structures, krypton occupancy 
in GBS I , krypton occupancy in GBS II and  krypton-induced expansion of GBS II. 
 
 
Fig. 9. Xenon and krypton occupancies as a function of pressure.  
A theoretical study based on a three-dimensional distribution function theory of molecular 
liquids was applied to lysozyme in presence of water and noble gases (Imai et al., 2007). This 
study predicted that krypton had a slightly better affinity for GBS II than xenon. Structures 
of lysozyme under higher pressure of krypton (30 and 40 bar) would be necessary to 
confirm this prediction.  
5.4 Structure of lysozyme under pressure of argon 
The structures of lysozyme under argon pressure of 10 to 50 bar were determined in the 
present study. Whatever the applied pressure, no argon was visible in the electron density 
map even at a pressure of 50 bar neither in GBS I or in GBS II. In GBS I, the water molecule 
was present at the exact place of the water molecule in the native gas-less structure. The 
smaller size of argon should not prevent argon to bind within GBS II, however, a higher 
pressure would probably be necessary to be able to visualize argon in the electron density 
map in GBS II. 
In the theoretical study already mentioned (Imai et al., 2007), argon affinity for GBS II was 
predicted to be very high. However, the present study showed that even at high pressure, 
argon did not bind within GBS II, even if it smaller size would allow its binding. Argon 
polarizability is lower than krypton and xenon polarizabilities (Table 1), due to its small 
number of electron, and could explain its very low affinity for lysozyme. 
5.5 Conclusion on lysozyme structures under inert gas pressure 
Lysozyme possesses two gas binding sites, one located in a pocket at a crystallographic 
interface (GBS I) and one located within a quite small internal cavity (GBS II). Both xenon 
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and krypton were bound within GBS II with a quite low occupation, and only xenon was 
bound within GBS I. Argon did not bind to lysozyme even at a pressure of 50 bar. The rule 
that showed that gas occupancy rose with gas size and polarizability is almost respected, 
since the small size of GBS II could prevent xenon binding and thus favour krypton binding. 
In the pressure range which would correspond to physiological conditions (5 – 10 bar), 
xenon occupancy is likely to be very low (less than 10 %), and krypton and argon 
occupancies are null. It is then likely than enzymatic activity of lysozyme is not modified by 
the presence of an inert gas. 
6. Conclusion 
Noble gases bind to proteins essentially through non-covalent van der Waals interactions, 
their binding constant depending on their electronic polarizability. In the three studied 
enzymes, gas occupancies were in the order of their polarizability, Xe > Kr > Ar, as it was 
already found for T4 lysozyme (Quillin et al., 2000). The only slight exception was the 
internal cavity of egg white lysozyme, where its smaller size prevented xenon higher 
occupancy. 
The major physiological targets of gaseous anesthetics are postulated to be neuronal 
channels receptors, like the NMDA receptor which is inhibited by xenon (Campagna et al., 
2003; Franks, 2008), or the GABAA receptor which could be modulated by argon (Abraini et 
al., 2003). However, at lower concentration, gas would bind mainly to globular targets, 
amongst them enzymes, whose functions would be modulated by the presence of inert gas. 
From the present study, we can infer different mode of inhibition by gas. In urate oxidase, 
gas inhibited the catalytic reaction through an indirect mechanism; the presence of the gas 
within the cavity would prevent the cavity contraction, thus modifying the active site 
flexibility. In elastase, gas inhibited the catalytic reaction through a direct mechanism; the 
presence of the gas in the active site would prevent the substrate binding. In lysozyme, gas 
would not inhibit the catalytic reaction, their occupation being too weak. 
Protein activity requires some conformational flexibility (Frauenfelder et al., 1991). In 
enzymes, the balance between conformational flexibility and rigidity is adjusted to optimize 
the catalytic efficiency for a given condition (Chiuri et al., 2009). Cavities would facilitate 
conformational changes and are though to play a key role in protein function (Hubbard et 
al., 1994). Anesthetics have been postulated to act by stabilizing high-energy conformers 
inducing altered functions (Eckenhoff, 2001; Johansson et al., 2005). High pressure was also 
postulated to stabilize high-energy conformers with altered functions (Frauenfelder et al., 
1990; Akasaka, 2006; Fourme et al., 2006). Urate oxidase is thus a key example which 
highlights the effect of anesthetic, since this enzyme is both inhibited by gas presence in a 
hydrophobic cavity (Marassio et al., 2011) and by high pressure (Girard et al., 2010). 
Inert gas binds to proteins through very weak non-covalent van der waals interaction. How 
such weak interactions could generate such high biological effect such as anesthesia ? It was 
suggested that anesthesia would arise from small effects at many biological targets (Eckenhoff, 
2001).  The present study would confirm this hypothesis, showing that some enzymes could be 
stabilized by the presence of gas in hydrophobic cavity (as in urate oxidase), some enzymes 
could be directly inhibited by gas (as in elastase case), and some enzymes are not affected by 
gas (as in the case of lysozyme). The mechanisms of neuroprotection and anesthesia by inert 
gases are thus very complex processes with many biological targets whose function are 
modulated (inhibited or potentiated) by the presence of gas.  
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